SCHEMBL895026

SCHEMBL895026

O=C(O)C1CCN(c2cc(C(F)(F)F)nc3ccccc23)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 3/20 0.64
MAPK1 P28482 1/20 0.61
MAPT P10636 1/20 0.60
DRD2 P14416 3/20 0.52
DRD3 P35462 3/20 0.52
DPP4 P27487 1/20 0.52
DPP8 Q6V1X1 1/20 0.52
DPP9 Q86TI2 1/20 0.52
TSHR P16473 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
PPARG P37231 1/20 0.47
ATM Q13315 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
NCF1 P14598 1/20 0.47
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3863739 0.81 NCF1 (0.70) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL30058990 0.80 ADRB2 (0.62) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL6595059 0.79 ADRB2 (0.73) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL23362148 0.79 ADRB2 (0.68) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL30058841 0.79 ADRB2 (0.68) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL2711296 0.78 ADRB2 (1.00) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL30058924 0.78 ADRB2 (1.00) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL6125222 0.78 ADRB2 (0.72) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL30061390 0.78 MAPT (0.57) ADRB2MAPK1MAPTDRD2DRD3
SCHEMBL23362808 0.78 MAPK1 (0.82) ADRB2MAPK1MAPTDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560978-B1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS INC (US) 2019-01-30 EP disclosed
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2018-09-06 US disclosed
US-9994594-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2018-06-12 US disclosed
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2017-06-29 US disclosed
US-9040703-B2 Inhibitors of arginase and their therapeutic applications MARS, INCORPORATED (US) 2015-05-26 US disclosed
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-12-18 US disclosed
EP-2560978-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS Mars, Incorporated (US) 2013-02-27 EP disclosed
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2012-04-05 US disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180251479-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 ADRB2 837/4885MAPK1 2450/4885MAPT 4496/4885
US-20170183362-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 ADRB2 837/4885MAPK1 2450/4885MAPT 4496/4885
US-20120083469-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 ADRB2 837/4885MAPK1 2450/4885MAPT 4496/4885
US-20140371175-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT9 ADRB2 837/4885MAPK1 2450/4885MAPT 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.